Bromhexine Use in Pediatric Population

Guideline-Based Recommendations

• The European Respiratory Society recommends that bromhexine should not be used routinely in children and adolescents with bronchiectasis due to concerns about potential adverse effects and lack of proven efficacy in the pediatric population (conditional recommendation, very low quality of evidence) 1
• The European Respiratory Society suggests that bromhexine is not used routinely in children/adolescents (conditional recommendation, very low quality of evidence) 1
• The guideline panel expressed concern that most clinicians would be very concerned about using bromhexine due to the potential adverse effects, which applies to the pediatric age range (0-18 years), including 12-month-old infants 2, 3

Evidence of Adverse Effects

• Studies showed increased adverse events with bromhexine compared to placebo (OR 2.93, 95% CI 0.12-73.97), though the confidence interval is wide due to small sample size 4
• The balance of evidence favours not using bromhexine routinely based on patient/parents values, the substantial adverse effects described above and the lack of efficacy of these treatments 5

Key Clinical Considerations

• All available evidence comes from adult-based randomized controlled trials, with no pediatric-specific studies identified by the European Respiratory Society systematic review 6
• The very low quality of evidence means there is substantial uncertainty about both efficacy and safety in children 1
• At 12 months of age, children have limited ability to cooperate with expectoration, making the theoretical benefit of a mucolytic agent questionable from a practical standpoint 5

Alternative Approaches

• Airway clearance techniques are strongly recommended by the European Respiratory Society for children with bronchiectasis, with individualized, age-appropriate methods taught by pediatric-trained physiotherapists 5
• These non-pharmacologic approaches avoid the adverse effect profile of mucolytic medications while providing proven benefit 3, 5

Avoidance of Bromhexine in Infants with Bronchiectasis

Recommendation Against Routine Use

• The European Respiratory Society issues a conditional recommendation (very low quality evidence) that bromhexine should not be used routinely in children and adolescents with bronchiectasis, extending to infants as young as 7 months. 7

Evidence Gap in Pediatric Populations

• No pediatric studies of bromhexine exist; all available data derive from adult randomized controlled trials, and systematic reviews have identified zero pediatric‑specific trials. 7

Preference for Non‑Pharmacologic Airway Clearance

• The European Respiratory Society strongly recommends individualized airway‑clearance techniques—delivered by pediatric‑trained chest physiotherapists and tailored to the child’s developmental level—as the preferred management for pediatric bronchiectasis. 7

Guidance When Medication Is Considered

• If any mucoactive medication is contemplated, clinicians should consult a pediatric pulmonologist or pediatrician for age‑appropriate alternatives, because the evidence base for such agents in infants is extremely limited. 7

Evidence Quality and Risk‑Benefit Assessment

• The overall evidence supporting bromhexine use in children is very low quality, creating substantial uncertainty regarding both efficacy and safety and rendering the risk‑benefit balance unfavorable. 7